Matteo Rosellini

1.8k total citations · 5 hit papers
49 papers, 1.2k citations indexed

About

Matteo Rosellini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Matteo Rosellini has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 15 papers in Surgery. Recurrent topics in Matteo Rosellini's work include Cancer Immunotherapy and Biomarkers (24 papers), Renal cell carcinoma treatment (20 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Matteo Rosellini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Renal cell carcinoma treatment (20 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Matteo Rosellini collaborates with scholars based in Italy, United States and Spain. Matteo Rosellini's co-authors include Francesco Massari, Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, Matteo Santoni, Nicola Battelli, Elisa Tassinari, Luca Faloppi, Valentina Tateo and Rodolfo Montironi and has published in prestigious journals such as International Journal of Molecular Sciences, European Urology and European Journal of Cancer.

In The Last Decade

Matteo Rosellini

45 papers receiving 1.2k citations

Hit Papers

Prognostic and predictive biomarkers for immunotherapy in... 2022 2026 2023 2024 2022 2022 2023 2023 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
    2022 138 citations Matteo Rosellini, Andrea Marchetti et al. Nature Reviews Urology profile →
  2. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
    2022 123 citations Matteo Santoni, Alessandro Rizzo et al. profile →
  3. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
    2023 117 citations Matteo Santoni, Alessandro Rizzo et al. Cancer Immunology Immunotherapy profile →
  4. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
    2023 115 citations Veronica Mollica, Alessandro Rizzo et al. Clinical and Experimental Medicine profile →
  5. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
    2023 107 citations Alessandro Rizzo, Veronica Mollica et al. Cancer Immunology Immunotherapy profile →

Peers

Matteo Rosellini
Andrea Marchetti Italy
Jiuda Zhao China
Juliana Guarize Italy
Xianshu Gao China
Alessia Mennitto Italy
Morena Fasano Italy
Pallavi S. Mishra‐Kalyani United States
Zhihuang Hu China
Koung Jin Suh South Korea
Edgardo S. Santos United States
Andrea Marchetti Italy
Matteo Rosellini
Citations per year, relative to Matteo Rosellini Matteo Rosellini (= 1×) peers Andrea Marchetti

Countries citing papers authored by Matteo Rosellini

Since Specialization
Citations

This map shows the geographic impact of Matteo Rosellini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Rosellini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Rosellini more than expected).

Fields of papers citing papers by Matteo Rosellini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Rosellini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Rosellini. The network helps show where Matteo Rosellini may publish in the future.

Co-authorship network of co-authors of Matteo Rosellini

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Rosellini. A scholar is included among the top collaborators of Matteo Rosellini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Rosellini. Matteo Rosellini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosellini, Matteo, Veronica Mollica, Andrea Marchetti, et al.. (2025). Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathology - Research and Practice. 270. 155964–155964.
2.
3.
Casadio, Chiara, Matteo Rosellini, Andrea Marchetti, et al.. (2024). Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. Journal of Clinical Medicine. 13(19). 5738–5738. 4 indexed citations
4.
Tassinari, Elisa, Andrea Marchetti, Matteo Rosellini, et al.. (2024). State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. Human Vaccines & Immunotherapeutics. 21(1). 2440165–2440165. 6 indexed citations
5.
Mollica, Veronica, Alessandro Rizzo, Andrea Marchetti, et al.. (2023). The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clinical and Experimental Medicine. 23(8). 5039–5049. 115 indexed citations breakdown →
6.
Rizzo, Alessandro, Veronica Mollica, Valentina Tateo, et al.. (2023). Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology Immunotherapy. 72(6). 1381–1394. 107 indexed citations breakdown →
7.
Santoni, Matteo, Alessandro Rizzo, Jakub Kucharz, et al.. (2023). Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology Immunotherapy. 72(6). 1365–1379. 117 indexed citations breakdown →
8.
Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907. 11 indexed citations
9.
Rizzo, Alessandro, Veronica Mollica, Andrea Marchetti, et al.. (2022). Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 14(17). 4142–4142. 10 indexed citations
10.
Mollica, Veronica, Elisa Tassinari, Andrea Marchetti, et al.. (2022). Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology. 29(3). 1709–1722. 9 indexed citations
11.
Rosellini, Matteo, Andrea Marchetti, Veronica Mollica, et al.. (2022). Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology. 20(3). 133–157. 138 indexed citations breakdown →
12.
Mollica, Veronica, Dario de Biase, Francesca Giunchi, et al.. (2022). A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. Pathology - Research and Practice. 236. 153983–153983. 3 indexed citations
13.
Mollica, Veronica, Andrea Marchetti, Matteo Rosellini, et al.. (2021). An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 22(24). 13519–13519. 18 indexed citations
14.
Mollica, Veronica, Alessandro Rizzo, Matteo Rosellini, et al.. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers. 13(3). 546–546. 37 indexed citations
15.
Marchetti, Andrea, Matteo Rosellini, Veronica Mollica, et al.. (2021). The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?. International Journal of Molecular Sciences. 22(12). 6237–6237. 20 indexed citations
16.
Rizzo, Alessandro, Veronica Mollica, Matteo Rosellini, et al.. (2021). Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Pathology - Research and Practice. 222. 153440–153440. 11 indexed citations
17.
Mollica, Veronica, Matteo Santoni, Marc Matrana, et al.. (2021). Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted Oncology. 17(1). 61–68. 68 indexed citations
18.
Massari, Francesco, Alessandro Rizzo, Veronica Mollica, et al.. (2021). Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer. 154. 120–127. 71 indexed citations
19.
20.
Capitanini, Alessandro, et al.. (2009). Wunderlich Syndrome during antiplatelet drug therapy. Clinical Nephrology. 71(3). 342–344. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Marchetti Breakdown of academic impact, for papers by Jiuda Zhao Breakdown of academic impact, for papers by Juliana Guarize Breakdown of academic impact, for papers by Xianshu Gao Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Morena Fasano Breakdown of academic impact, for papers by Pallavi S. Mishra‐Kalyani Breakdown of academic impact, for papers by Zhihuang Hu Breakdown of academic impact, for papers by Koung Jin Suh Breakdown of academic impact, for papers by Edgardo S. Santos
Rankless by CCL
2026